Your browser doesn't support javascript.
loading
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
Isa, Flonza; Forleo-Neto, Eduardo; Meyer, Jonathan; Zheng, Wenjun; Rasmussen, Scott; Armas, Danielle; Oshita, Masaru; Brinson, Cynthia; Folkerth, Steven; Faria, Lori; Heirman, Ingeborg; Sarkar, Neena; Musser, Bret J; Bansal, Shikha; O'Brien, Meagan P; Turner, Kenneth C; Ganguly, Samit; Mahmood, Adnan; Dupljak, Ajla; Hooper, Andrea T; Hamilton, Jennifer D; Kim, Yunji; Kowal, Bari; Soo, Yuhwen; Geba, Gregory P; Lipsich, Leah; Braunstein, Ned; Yancopoulos, George D; Weinreich, David M; Herman, Gary A.
Afiliación
  • Isa F; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. Electronic address: flonza.isa@regeneron.com.
  • Forleo-Neto E; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. Electronic address: eduardo.forleoneto@regeneron.com.
  • Meyer J; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Zheng W; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Rasmussen S; Celerion, Lincoln, NE, USA.
  • Armas D; Celerion, Tempe, AZ, USA.
  • Oshita M; Benchmark Research, Sacramento, CA, USA.
  • Brinson C; Central Texas Clinical Research, LLC, Austin, TX, USA.
  • Folkerth S; Midwest Clinical Research Center, LLC, Dayton, OH, USA.
  • Faria L; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Heirman I; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Sarkar N; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Musser BJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Bansal S; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • O'Brien MP; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Turner KC; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Ganguly S; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Mahmood A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Dupljak A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Hooper AT; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Hamilton JD; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Kim Y; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Kowal B; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Soo Y; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Geba GP; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Lipsich L; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Braunstein N; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Yancopoulos GD; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Weinreich DM; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Herman GA; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Int J Infect Dis ; 122: 585-592, 2022 Sep.
Article en En | MEDLINE | ID: mdl-35788416
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Etiology_studies Límite: Adult / Humans Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Etiology_studies Límite: Adult / Humans Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article